1-3 of 3
Sophie Betteridge
Close
Sort by
Journal Articles

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Clinical Trials & Observations
Nigel Russell, Alan Burnett, Robert Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanovic, Richard Dillon, David Grimwade
Journal: Blood
Blood (2018) 132 (13): 1452–1454.
https://doi.org/10.1182/blood-2018-05-851824
Published: 2018
Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath
Journal: Blood
Blood (2016) 128 (22): 897.
https://doi.org/10.1182/blood.V128.22.897.897
Published: 2016
Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD
Journal: Blood
Blood (2015) 126 (23): 559.
https://doi.org/10.1182/blood.V126.23.559.559
Published: 2015